MX2016013048A - Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras. - Google Patents

Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras.

Info

Publication number
MX2016013048A
MX2016013048A MX2016013048A MX2016013048A MX2016013048A MX 2016013048 A MX2016013048 A MX 2016013048A MX 2016013048 A MX2016013048 A MX 2016013048A MX 2016013048 A MX2016013048 A MX 2016013048A MX 2016013048 A MX2016013048 A MX 2016013048A
Authority
MX
Mexico
Prior art keywords
treatment
inhibitor
combination
nras
mutated cancer
Prior art date
Application number
MX2016013048A
Other languages
English (en)
Other versions
MX369111B (es
Inventor
Anthony Edward Cross Darren
Anne Eberlein Catherine
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2016013048A publication Critical patent/MX2016013048A/es
Publication of MX369111B publication Critical patent/MX369111B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a los métodos para identificar resistencia a la terapia para cáncer, mediante la identificación de una mutación E63K NRAS, una mutación G12V NRAS o una ganancia del número de copias del gen NRAS. Un aspecto adicional de la invención se refiere a métodos de tratamiento que pueden superar tales mecanismos de resistencia, que implican el uso de un inhibidor de EGFR en combinación con un inhibidor de MEK para el tratamiento de cánceres que implican una mutación NRAS seleccionada de E63K, G12V, G12R, G12A, G12D, G12S y G12C, y/o cáncer que implica una ganancia del número de copias del gen NRAS.
MX2016013048A 2014-04-04 2015-04-02 Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras. MX369111B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461975088P 2014-04-04 2014-04-04
US201462013573P 2014-06-18 2014-06-18
PCT/GB2015/051042 WO2015150826A1 (en) 2014-04-04 2015-04-02 Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer

Publications (2)

Publication Number Publication Date
MX2016013048A true MX2016013048A (es) 2017-04-27
MX369111B MX369111B (es) 2019-10-29

Family

ID=52824498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013048A MX369111B (es) 2014-04-04 2015-04-02 Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras.

Country Status (15)

Country Link
US (2) US20200237758A1 (es)
EP (1) EP3125885B1 (es)
JP (1) JP6549147B2 (es)
KR (1) KR102406334B1 (es)
CN (1) CN106456774A (es)
AU (1) AU2015242407B2 (es)
CA (1) CA2943402C (es)
DK (1) DK3125885T3 (es)
ES (1) ES2890556T3 (es)
HU (1) HUE055747T2 (es)
MA (1) MA39841A (es)
MX (1) MX369111B (es)
PL (1) PL3125885T3 (es)
RU (1) RU2683276C2 (es)
WO (1) WO2015150826A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018013413A (es) 2016-05-26 2019-06-06 Zeno Royalties & Milestones Llc Compuestos inhibidores de egfr.
WO2018218633A1 (en) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176740A1 (en) * 2002-04-08 2005-08-11 Spector Neil L. Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
MX2011005002A (es) * 2008-11-11 2011-05-25 Lilly Co Eli Inhibidor de p70 s6 quinasa y terapia de combinacion de inhibidor del receptor de egfr.
PL3686194T3 (pl) * 2011-07-27 2022-01-17 Astrazeneca Ab Związki 2-(2,4,5-podstawione-anilino)pirymidynowe
DK2797957T3 (da) * 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
WO2014028909A1 (en) * 2012-08-16 2014-02-20 Ohio State Innovation Foundation Stat3 inhibitors and their anticancer use
US20140066465A1 (en) * 2012-09-04 2014-03-06 The Cleveland Clinic Foundation CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS

Also Published As

Publication number Publication date
US20210177844A1 (en) 2021-06-17
JP6549147B2 (ja) 2019-07-24
DK3125885T3 (da) 2021-09-27
HUE055747T2 (hu) 2021-12-28
US20200237758A1 (en) 2020-07-30
ES2890556T3 (es) 2022-01-20
MA39841A (fr) 2017-02-08
AU2015242407B2 (en) 2017-11-09
CN106456774A (zh) 2017-02-22
RU2016140626A (ru) 2018-05-07
MX369111B (es) 2019-10-29
JP2017511341A (ja) 2017-04-20
RU2016140626A3 (es) 2018-10-23
KR20160135362A (ko) 2016-11-25
WO2015150826A1 (en) 2015-10-08
KR102406334B1 (ko) 2022-06-07
PL3125885T3 (pl) 2021-12-06
RU2683276C2 (ru) 2019-03-27
EP3125885B1 (en) 2021-06-30
CA2943402C (en) 2022-12-13
EP3125885A1 (en) 2017-02-08
CA2943402A1 (en) 2015-10-08
AU2015242407A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
EP3287774B8 (en) Data processing device for x-ray examination, and computer implemented data processing method
MX2015000193A (es) Metodo y dispositivo para ocultar informacion de privacidad.
MX2018002741A (es) Metodo y aparato para determinar datos volumetricos de una caracteristica anatomica predeterminada.
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
MX2015015605A (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
GB2538022B (en) Multiple secrets in quorum based data processing
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
MX2019013634A (es) Composiciones y metodos para tratar cancer con mutaciones de braf atipicas.
MX357934B (es) Determinación de la ubicación de un ocupante de veículo.
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
HUE046115T2 (hu) Együttmûködésen alapuló táblázatkezelõ adat validálás és integrálás
MX2019000775A (es) Linea de montaje con inspeccion visual elctronica integrada.
GB201615266D0 (en) Data processing apparatuses, methods, computer programs and computer-readable media
NZ752443A (en) Lasofoxifene treatment of er+ breast cancer
MX2016013048A (es) Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras.
BR112018013269A2 (pt) composições e métodos para a avaliação do risco de ocorrência do câncer
MX2019001214A (es) Metodos para el diagnostico de neoplasia de origen ginecologico.
AU2015201541B2 (en) Multimodal biometric profiling
WO2014140061A3 (en) Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene
GB2599566B (en) Data processing apparatuses, methods, computer programs and computer-readable media
CY1124668T1 (el) Χρηση των αναστολεων c-met για την αγωγη καρκινων που φερουν μεταλλαγες met
EP3663909A4 (en) INFORMATION PROCESSING DEVICE AND FILE COPY PROCESS
PL3545109T3 (pl) Sposób identyfikacji in vitro gruczolaków jelita grubego lub raka jelita grubego

Legal Events

Date Code Title Description
FG Grant or registration